CONMED Corporation announced preliminary financial information for the third quarter of 2024, projecting revenue in the range of $315 million to $318 million. This preliminary revenue range is below the consensus estimate of $318.73 million.
Despite the revenue outlook, the company anticipates adjusted diluted net earnings per share growth to exceed its previously provided guidance of 9% to 11%. This suggests stronger-than-expected profitability despite top-line performance.
CONMED is scheduled to report its full financial results for the third quarter of 2024 on October 30, 2024. This preliminary release provides an early glimpse into the company's performance ahead of the detailed report.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.